Global Anti-Malarial Drugs Market by Drug Type (Chloroquine, Artemisinin-Based Combination Therapies (ACT), Hydroxychloroquine, Mefloquine, Atovaquone-Proguanil), by Administration Route (Oral, Injectable, Intravenous), by Application (Malaria Prevention, Malaria Treatment, Malaria Relapse Management); Insights & Forecast (2024 ? 2030)

As per Intent Market Research, the Anti-Malarial Drugs Market was valued at USD 6.2 Billion in 2024-e and will surpass USD 9.5 Billion by 2030; growing at a CAGR of 7.3% during 2025 - 2030.

The anti-malarial drugs market is crucial in the global fight against malaria, a life-threatening disease caused by Plasmodium parasites transmitted through the bites of infected mosquitoes. Malaria remains a significant health burden, especially in sub-Saharan Africa, Southeast Asia, and parts of Latin America. The market is driven by the rising incidence of malaria in endemic regions and the ongoing need for both prevention and treatment solutions. Anti-malarial drugs play a key role in reducing mortality rates and controlling the spread of the disease, contributing to public health initiatives worldwide.

The market for anti-malarial drugs is highly influenced by evolving treatment regimens, the development of combination therapies, and increasing resistance to traditional therapies, such as chloroquine. Governments, non-governmental organizations, and international health bodies are actively involved in supporting and promoting the use of effective anti-malarial drugs, particularly in regions where malaria is endemic. Additionally, innovation in drug formulations and the development of new drug combinations are expected to drive growth in the market.

Artemisinin-Based Combination Therapies (ACT) Are the Fastest Growing Drug Type Due to Their Effectiveness

Artemisinin-Based Combination Therapies (ACT) are the fastest-growing drug type in the anti-malarial drugs market. These therapies combine artemisinin or its derivatives with another anti-malarial drug to enhance efficacy and reduce the likelihood of drug resistance, which is a growing concern with single-drug therapies. ACTs have become the first-line treatment for uncomplicated Plasmodium falciparum malaria, the most deadly form of the disease. The World Health Organization (WHO) endorses ACTs due to their ability to rapidly reduce parasitemia and lower mortality rates.

ACTs are particularly effective in treating drug-resistant malaria strains, which has fueled their adoption in malaria-endemic regions. Their broad use in global malaria control programs and increasing availability through international health organizations are key drivers of the market's growth. As the fight against malaria intensifies, ACTs continue to be central to treatment protocols, reinforcing their growing market share.

Hospitals Are the Largest End-Use Industry Due to High Treatment Demand

Hospitals are the largest end-use industry for anti-malarial drugs, primarily due to the need for immediate and effective treatment of severe malaria cases. In hospital settings, anti-malarial drugs are administered to patients with complicated or severe forms of malaria, where rapid action is critical to prevent death. Injectable and intravenous forms of anti-malarial drugs, such as artesunate and quinine, are commonly used in these settings to treat patients who are unable to tolerate oral medications.

Hospitals also serve as the central hubs for malaria treatment in areas with high disease prevalence. Due to the severity of malaria in these regions, hospitals play an essential role in diagnosing and managing both prevention and treatment protocols. As malaria remains a leading cause of morbidity and mortality, especially in tropical regions, hospitals will continue to be the primary setting for anti-malarial drug usage, particularly for severe cases requiring intensive care.

Africa Is the Largest Region Due to High Malaria Incidence

Africa is the largest region in the anti-malarial drugs market, driven by the high prevalence of malaria, particularly in sub-Saharan Africa. The World Health Organization (WHO) estimates that Africa accounts for more than 90% of global malaria cases and deaths, making it the largest market for anti-malarial drugs. The high demand for malaria prevention and treatment, coupled with the need for effective interventions, has resulted in the region being the largest consumer of anti-malarial medications.

The continuous efforts of governments, international organizations, and non-governmental agencies to combat malaria in the region have led to increased access to anti-malarial drugs, including ACTs and other treatments. Africa's role in the global anti-malarial drugs market is expected to remain significant as the region works toward achieving malaria elimination, supported by initiatives to ensure affordable access to treatment.

Competitive Landscape and Key Players

The competitive landscape of the anti-malarial drugs market is dominated by key players such as Novartis, GlaxoSmithKline, Sanofi, and Cipla, who are at the forefront of developing and distributing anti-malarial therapies. These companies offer a wide range of drugs, from traditional treatments like chloroquine to newer combination therapies such as Artemisinin-Based Combination Therapies (ACTs). In addition, generics play a significant role in the market, providing more affordable treatment options in malaria-endemic regions.

The market is also characterized by ongoing research and development efforts aimed at overcoming the challenges of drug resistance and improving the efficacy of treatments. As malaria resistance to existing treatments continues to rise, pharmaceutical companies are exploring novel drug combinations and formulations to meet the growing demand for effective treatments. Partnerships between governments, global health organizations, and pharmaceutical companies will continue to shape the future of the anti-malarial drugs market, with a focus on ensuring access to life-saving therapies in malaria-endemic regions.

Recent Developments:

• Novartis AG launched a new artemisinin-based combination therapy to combat drug-resistant malaria strains in Sub-Saharan Africa.
• GlaxoSmithKline (GSK) introduced a novel malaria vaccine designed to complement existing anti-malarial drugs and reduce transmission.
• Sanofi announced a partnership with Médecins Sans Frontières to distribute anti-malarial drugs at lower prices in malaria-endemic regions.
• AstraZeneca PLC received approval for a new injectable anti-malarial drug targeting severe malaria cases for fast recovery.
• Cipla Limited launched an oral anti-malarial drug combination for malaria treatment in emerging markets.

List of Leading Companies:

• Novartis AG
• GSK (GlaxoSmithKline PLC)
• Sanofi
• Pfizer Inc.
• Bristol-Myers Squibb
• Mylan Pharmaceuticals Inc.
• AstraZeneca PLC
• Merck & Co., Inc.
• Lupin Pharmaceuticals
• Artesun Pharmaceuticals
• Cipla Limited
• Sun Pharmaceutical Industries Ltd.
• Dr. Reddy's Laboratories Ltd.
• Hetero Drugs Ltd.
• Alvogen

Report Scope: